Dario Lidonnici

Dario Lidonnici

Auto-generated profile, based on publicly available information

Dario Lidonnici

More Than Access (MTA) Srl SB, Milan, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MBManuela Basso
Manuela Basso
SPSilvia Pozzi
Silvia Pozzi
MTMassimo Tortarolo
Massimo Tortarolo
FFFabio Fiordaliso
Fabio Fiordaliso
CBCinzia Bisighini
Cinzia Bisighini
VBValentina Bonetto
Valentina Bonetto
Amyotrophic lateral sclerosis is the most common motor neuron disease and is still incurable. The mechanisms leading to the selective motor neuron vulnerability are still not known. The interplay between motor neurons and astrocytes is crucial in the outcome of the disease. We show that mutant copper-zinc superoxide dismutase (SOD1) overexpression in primary astrocyte cultures is associated with decreased levels of proteins involved in secretory pathways. This is linked to a general reduction of total secreted proteins, except for specific enrichment in a number of proteins in the media, such as mutant SOD1 and valosin-containing protein (VCP)/p97. Because there was also an increase in exosome release, we can deduce that astrocytes expressing mutant SOD1 activate unconventional secretory pathways, possibly as a protective mechanism. This may help limit the formation of intracellular aggregates and overcome mutant SOD1 toxicity. We also found that astrocyte-derived exosomes efficiently transfer mutant SOD1 to spinal neurons and induce selective motor neuron death. We conclude that the expression of mutant SOD1 has a substantial impact on astrocyte protein secretion pathways, contributing to motor neuron pathology and disease spread.

4 June 2015 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
MTMassimo Tortarolo
Massimo Tortarolo
AVAntonio Vallarola
Antonio Vallarola
DLDario Lidonnici
Dario Lidonnici
EBElisa Battaglia
Elisa Battaglia
FGFrancesco Gensano
Francesco Gensano
CBCaterina Bendotti
Caterina Bendotti

1 March 2012 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
Marco PevianiMarco Peviani
Marco Peviani
MKMami Kurosaki
Mami Kurosaki
mineko teraomineko terao
mineko terao
DLDario Lidonnici
Dario Lidonnici
FGFrancesco Gensano
Francesco Gensano
CBCaterina Bendotti
Caterina Bendotti

15 August 2023 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Open access
PDF file
GCGiorgio Casilli
Giorgio Casilli
DLDario Lidonnici
Dario Lidonnici
CJClaudio Jommi
Claudio Jommi
MNMarika De Nigris
Marika De Nigris
AGArmando A. Genazzani
Armando A. Genazzani
Objectives: The Health Technology Assessment (HTA) of medicines is performed separately at the country level with some differences, but Italy, France, and Germany have implemented price and reimbursement systems strongly focused on the Added Therapeutic Value (ATV). This study investigates the level of agreement on ATV assessments by Agenzia Italiana del Farmaco (AIFA), Haute Autorité de Santé (HAS), and Gemeinsamer Bundesausschuss (G-BA). Methods: A database was created collecting all information about drugs with innovativeness status requests in Italy from July 2017 to December 2022 and populated with the corresponding HAS and G-BA ATV assessments. The primary comparative analysis was conducted by grouping the ATV ratings into “higher added value” and “lower or no added value”, while a secondary analysis considered the Italian innovativeness status as a criterion to include the quality of evidence assessment. The concordance between ATV assessments was investigated through percentage agreement and unweighted Cohen k-value. Results: 189 medicines/indications were included. The greatest agreement was found when comparing G-BA versus HAS (82 percent; k = 0.61, substantial agreement). Lower levels of agreements were observed for AIFA versus HAS and AIFA versus G-BA (respectively 52 percent; k = 0.17 and 57 percent; k = 0.25). The secondary analysis led to a reconciliation to moderate agreement for AIFA versus HAS (72 percent; k = 0.45) and AIFA versus G-BA (74 percent; k = 0.47). Conclusions: A high degree of concordance between HTA organizations is reached when considering jointly ATV and quality of evidence, suggesting that the system is extensively mature to make a Joint Clinical Assessment, avoiding duplications and reducing access inequalities.

27 April 2015 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Closed access
FRFederica Romano
Federica Romano
MRMatteo Ruggeri
Matteo Ruggeri
SCSilvia Coretti
Silvia Coretti
Edoardo Giovanni GianniniEdoardo Giovanni Giannini
Edoardo Giovanni Giannini
DSDario Sacchini
Dario Sacchini
DLDario Lidonnici
Dario Lidonnici
OBJECTIVE: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia.\ud METHODS: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN.\ud RESULTS: Base case results demonstrate that scenario 1 is associated with a cost per QALY of €30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of €32,752.44 per QALY when scenario 1 is compared with scenario 3.\ud CONCLUSION: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease

1 November 2015 in Value in Health
Verified
Journal Article
Closed access
DLD Lidonnici
D Lidonnici
ELEp Lanati
Ep Lanati